Some companies just flutter around trying to strategize how to get operations rolling while others seem to have it all under control by continuously moving forward with operations, revenues and expansion. Vicor Technologies certainly qualifies as the latter of those two types. No catalyst is needed to keep the Company driving forward with their proprietary PD2i® technology. The groundwork was laid in the prior years and since expanding its sales force in the third quarter of 2010, Vicor has not been shy of announcements showcasing the growth of revenues and distribution.
Yesterday, Vicor announced another significant move to broaden their footprint globally by signing a distribution agreement with Hadar Training and Medical Services to serve as its exclusive agent for PD2i Analyzer™, PD2i CA™(Cardiac Analyzer) and PD2i VS™ (Vital Sign) in Israel and Palestine. Operating since 1987, Hadar is an industry leader in providing first aid, resuscitation, EMT and Advanced Trauma Life Support (ATLS) as well as trauma training and medical programs. Hadar is also a leader in the importation and marketing of emergency medical equipment to community and field hospitals, and in the conversion and supply of mobile intensive care units and ambulances.
This new agreement is a perfect fit for Vicor and its revolutionary technology that has been dubbed “the new vital sign” given its propensity to accurately diagnose trauma patients and risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.
Vicor CEO David Fater commented, “We’re extremely pleased to have HADAR representing our PD2i® products. Hadar is a leader in the importation and marketing of emergency medical equipment to the Israeli community and field hospitals. Hadar will obtain approval from the Israel Ministry of Health and any other required regulatory authorities for the marketing of our products at its expense. We are confident that Hadar will be successful in securing the necessary regulatory approvals for our products as quickly as possible and are excited by the prospect of having our PD2i® products made available throughout the Israeli emergency medical community.”
As mentioned, Vicor is motivated and expanding rapidly and doing it while keeping its share structure firmly intact. With only approximately 46 million shares outstanding and less than 37 million in the float, investors may soon be taking notice of the Company as the PD2i®-based products continue to be used worldwide; which could lead to future press releases along the lines of the one announced two weeks ago detailing revenues from January 2011 topping totals from the whole fourth quarter of 2010.
More information on Vicor Technologies and its PD2i® technologies can be found on the Company’s website at www.vicortech.com. Investors can learn more about Hadar Training and Medical Services at www.hadar-medical.co.il